S2 tumours exhibited lower levels of pro-inflammatory or activated immune subsets: including GB+CD16+CD56+ active NK cells (C2, p = 0.0471, S2 vs S3), PD-1−GB+CD45RO+ (C6, p = 0.0220, S1 vs S2), and PD-1−CD69+CD45RO+ (C9, p = 0.009, S1 vs S2; p = 0.0184, S2 vs S3) active memory CD8+ T cells (Fig. 2d). The gene discussed is NCAM1; the disease is neoplasm.